Device Trial Radar · NCT02857816
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
Last checked: Nov 20, 2026Latest source record: Jan 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Sep 2016
Primary completion
Nov 21, 2017
Study completion Nov 21, 2017
Sponsor
- Lead sponsor
- MedtronicNeuroNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 5, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
Conditions
- Overactive Bladder
Interventions
NURO System PTNM TherapyDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Number of Urinary Urge Incontinence (UUI) Episodes Per Day After the 12th PTNM Therapy Sessions From BaselineTime frame: 12 Weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Pinellas Urology, Inc.
St. Petersburg, Florida
NorthShore University Health System
Evanston, Illinois
Mount Auburn Hospital
Cambridge, Massachusetts
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.